Carbylan Therapeutics Announces Decision to Pursue Strategic Transaction
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
JMP Securities Downgrades Carbylan Therapeutics (CBYL) to Market Perform
April 18, 2016 8:13 AM EDTJMP Securities downgraded Carbylan Therapeutics (NASDAQ: CBYL) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Carbylan Therapeutics click here. For more ratings news on Carbylan Therapeutics click here.
Shares of Carbylan Therapeutics closed at $0.64 yesterday.
... More